Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC)

Lukas C. Amler,Michael S. Gordon,Andreas Strauss,Nusrat Rabbee,Mika K. Derynck,K. Krueger,David A. Eberhard,Daniela Matei,Beth Y. Karlan

Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC)

2016

Lukas C. Amler
Michael S. Gordon
Andreas Strauss
Nusrat Rabbee
Mika K. Derynck
K. Krueger
David A. Eberhard
Daniela Matei
Beth Y. Karlan

3001 Background: Pertuzumab (P), a humanized HER2 antibody, represents a new class of targeted agents called HER dimerization inhibitors (HDIs). P inhibits dimerization of HER2 with EGFR, HER3 and ...

Keywords:

Pathology
Ovarian cancer
HER2 Antibody
Pertuzumab
Cancer research
Medicine
advanced ovarian cancer
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations